Biogen Inc.
BIIBNext catalyst
Felzartamab
Primary Membranous Nephropathy
Get an email about BIIB's next catalysts
Track Biogen (BIIB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 13 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
14 upcoming, 2 past
Felzartamab Phase 3 Est. Readout (TRANSCEND)
Primary completion for Felzartamab trial (NCT06685757) in Antibody-mediated Rejection
SourceLecanemab SC Phase 3 Est. Readout (Clarity AD)
Estimated primary completion for Lecanemab SC trial (NCT03887455) in Early Alzheimer's Disease. Topline data typically follows completion by weeks to months.
SourceTofersen Phase 2 Est. Readout
Estimated primary completion for Tofersen trial (NCT07294144) in ALS (Amyotrophic Lateral Sclerosis). Topline data typically follows completion by weeks to months.
Sourceanti-TNF therapy Phase 3 Est. Readout (CRI-RA)
Estimated primary completion for anti-TNF therapy trial (NCT04870203) in Rheumatoid Arthritis. Topline data typically follows completion by weeks to months.
SourceBIIB017 (peginterferon beta-1a) Phase 3 Est. Readout
Primary completion for BIIB017 (peginterferon beta-1a) trial (NCT03958877) in Multiple Sclerosis, Relapsing-Remitting
SourceFelzartamab Phase 3 Est. Readout (PREVAIL)
Primary completion for Felzartamab trial (NCT06935357) in Immunoglobulin A Nephropathy (IgAN)
SourceAPL-3007, pegcetacoplan (APL-2) Phase 2 Est. Readout
Primary completion for APL-3007, pegcetacoplan (APL-2) trial (NCT07215390) in Geographic Atrophy Secondary to Age-related Macular Degeneration
SourcePegcetacoplan Phase 3 Est. Readout
Primary completion for Pegcetacoplan trial (NCT05809531) in C3G
SourceHow BIIB's past catalysts played out
Market Overview
Stock performance and key metrics
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
WebsiteLeqembi
Lecanemab
Alzheimer Disease
Tofersen
ALS (SOD1)
Citalopram
Depressive Disorder, Major
APL2
FSGS
Lecanemab SC
Early Alzheimer's Disease
Lecanemab IV
Early Alzheimer's Disease
Pegcetacoplan
C3G
Dextromethorphan
Relapsing-Remitting Multiple Sclerosis
SAGE 217
Postpartum Depression
BIIB019 (Daclizumab)
Relapsing-Remitting Multiple Sclerosis
S-warfarin
Relapsing-Remitting Multiple Sclerosis
Avonex
Multiple Sclerosis
dimethyl fumarate
Relapsing-Remitting Multiple Sclerosis
Salanersen
Muscular Atrophy, Spinal
Midazolam
Relapsing-Remitting Multiple Sclerosis
natalizumab
Crohn's Disease
BG00012
Multiple Sclerosis
SAGE-217
Bipolar Disorder I
Litifilimab
Lupus Erythematosus, Systemic
Natalizumab (BG00002)
Multiple Sclerosis
BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
Felzartamab
Primary Membranous Nephropathy
Nusinersen
Muscular Atrophy, Spinal
BIIB017
Relapsing Multiple Sclerosis
BIIB041 (Fampridine-SR)
Multiple Sclerosis
peginterferon beta-1a
Relapsing Multiple Sclerosis
ALKS 8700
Relapsing Remitting Multiple Sclerosis
BIIB041 (fampridine)
Multiple Sclerosis, Remittent Progressive
BIIB019 (Daclizumab High Yield Process)
Relapsing-Remitting Multiple Sclerosis
BG9418 (Interferon beta-1a)
Active Ulcerative Colitis
Glatiramer Acetate
Relapsing-Remitting Multiple Sclerosis
fampridine
Multiple Sclerosis
BG00012 (dimethyl fumarate)
Healthy
BG00002 (natalizumab)
Multiple Sclerosis, Relapsing-Remitting
Alefacept
Chronic Plaque Psoriasis
Omaveloxolone
Friedreich Ataxia
Bardoxolone Methyl
Alport Syndrome
Interferon Beta-1a
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interferon β-1a
Relapsing-Remitting Multiple Sclerosis
tonapofylline
Renal Insufficiency
Diroximel fumarate
Relapsing Forms of Multiple Sclerosis
lixivaptan
Hyponatremia
Sertraline
Depressive Disorder, Major
Rituxan, Cyclophosphamide, Vincristine, Prednisone
Immune Thrombocytopenic Purpura
baricitinib treatment
Rheumatoid Arthritis
Mycophenolate Mofetil (cellcept)
Multiple Sclerosis
anti-TNF therapy
Rheumatoid Arthritis
Anti-inflammatory drugs
Rheumatoid Arthritis
ASA
Healthy
rituximab [MabThera/Rituxan]
Rheumatoid Arthritis
Desvenlafaxine
Depressive Disorder, Major
BIIB033
Multiple Sclerosis
MOR202
Glomerulonephritis
BIIB147
Amyotrophic Lateral Sclerosis
BCNU
Lymphoma
Transitioning patients from cyclosporine to alefacept
Psoriasis
Rituxan
Lymphoma
Bardoxolone methyl capsules
IgA Nephropathy
Mechanism of action of alefacept
Psoriasis
BIIB111
Choroideremia
Levodopa
Parkinson Disease
Chemotherapy and Radioimmunotherapy
Non-Hodgkin Lymphoma
90-Y-ibritumomab tiuxetan
Lymphoma
Bardoxolone Methyl (RTA 402)
Chronic Kidney Disease
natalizumab IV
Relapsing-Remitting Multiple Sclerosis
BG00002-E (natalizumab high titer)
Multiple Sclerosis
Ad.hIFN-β (BG00001, IDEC-201)
Colorectal Carcinoma
IDEC-114
Non-Hodgkin's Lymphoma
tetanus diphtheria toxoids vaccine
Relapsing Forms of Multiple Sclerosis
Baminercept alfa 1
Rheumatoid Arthritis
BIIB074
Primary Inherited Erythromelalgia
VP -16
Lymphoma
Omaveloxolone Capsules (/capsule)
Melanoma
Omaveloxolone Lotion
Breast Cancer
Bardoxolone methyl (amorphous dispersion)
Renal Insufficiency, Chronic
Yttrium-ibritumomab (Zevalin)
Lymphoma, Mantle-Cell
BIIB080
Alzheimer Disease
Omaveloxolone Ophthalmic
Inflammation and Pain Following Ocular Surgery
APL-3007, pegcetacoplan (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
RTA 402 (Bardoxolone Methyl)
Diabetic Nephropathy
Antiparkinsonian Agent(s)
Parkinson Disease
Diranersen
Mild Cognitive Impairment Due to Alzheimer's Disease
BIIB059 (litifilimab)
Systemic Lupus Erythematosus
Baminercept alfa 3
Rheumatoid Arthritis
Baminercept alfa 4
Rheumatoid Arthritis
Baminercept alfa 2
Rheumatoid Arthritis
Baminercept alfa 5
Rheumatoid Arthritis
CVP
Non-Hodgkins Lymphoma
In Zevalin
Lymphoma
BG00011
Idiopathic Pulmonary Fibrosis (IPF)
Ibritumomab Tiuxetan
Non-Hodgkins Lymphoma
interferon beta 1-a
Relapsing Remitting Multiple Sclerosis
meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)
Relapsing Forms of Multiple Sclerosis
BIIB033 (anti-LINGO-1 mAb)
Acute Optic Neuritis
DRF
Relapsing Forms of Multiple Sclerosis
exemestane (Aromasin)
Breast Cancer
trivalent seasonal influenza vaccine
Relapsing-Remitting Multiple Sclerosis
BIIB122
Parkinson Disease
Methylprednisolone
Graft Versus Host Disease
Zevalin Radioimmunotherapy
Lymphoma
BIIB091
Relapsing Forms of Multiple Sclerosis
SAGE-324
Essential Tremor
CHOP
Non-Hodgkins Lymphoma
natalizumab SC
Relapsing-Remitting Multiple Sclerosis
Y Zevalin
Lymphoma
Bardoxolone methyl oral capsule
Chronic Kidney Diseases
CNV1014802
Lumbosacral Radiculopathy
BIIB104
Cognitive Impairment Associated With Schizophrenia
Lumiliximab with FCR
Chronic Lymphocytic Leukemia
BG9924
Rheumatoid Arthritis
BIIB021
GIST
Omaveloxolone Opthalmic
Inflammation and Pain Following Ocular Surgery
BIIB041 (PR Fampridine)
Multiple Sclerosis
Zevalin
Lymphoma
90Y Zevalin
Non-Hodgkins Lymphoma
Lecanemab
Alzheimer's Disease
BG00010
Painful Lumbar Radiculopathy
Ibritumomab Tiuxetan (Zevalin)
Lymphoma
BIIB014
Parkinson's Disease
Tyruko Injectable Product
Multiple Sclerosis
BIIB112
X-Linked Retinitis Pigmentosa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leqembi Lecanemab | Approved | Alzheimer Disease | Fast TrackBreakthrough | - |
Tofersen | Approved | ALS (SOD1) | OrphanFast TrackBreakthrough | |
Citalopram | Phase 3 | Depressive Disorder, Major | - | - |
APL2 | Phase 3 | FSGS | - | - |
Lecanemab SC | Phase 3 | Early Alzheimer's Disease | - | - |
Lecanemab IV | Phase 3 | Early Alzheimer's Disease | - | - |
Pegcetacoplan | Phase 3 | C3G | - | - |
Dextromethorphan | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
SAGE 217 | Phase 3 | Postpartum Depression | - | - |
BIIB019 (Daclizumab) | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
S-warfarin | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Avonex | Phase 3 | Multiple Sclerosis | - | - |
dimethyl fumarate | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Salanersen | Phase 3 | Muscular Atrophy, Spinal | - | - |
Midazolam | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
natalizumab | Phase 3 | Crohn's Disease | - | - |
BG00012 | Phase 3 | Multiple Sclerosis | - | - |
SAGE-217 | Phase 3 | Bipolar Disorder I | - | - |
Litifilimab | Phase 3 | Lupus Erythematosus, Systemic | - | - |
Natalizumab (BG00002) | Phase 3 | Multiple Sclerosis | - | - |
BIIB017 (peginterferon beta-1a) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Felzartamab | Phase 3 | Primary Membranous Nephropathy | - | - |
Nusinersen | Phase 3 | Muscular Atrophy, Spinal | - | - |
BIIB017 | Phase 3 | Relapsing Multiple Sclerosis | - | - |
BIIB041 (Fampridine-SR) | Phase 3 | Multiple Sclerosis | - | - |
peginterferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - | - |
ALKS 8700 | Phase 3 | Relapsing Remitting Multiple Sclerosis | - | - |
BIIB041 (fampridine) | Phase 3 | Multiple Sclerosis, Remittent Progressive | - | - |
BIIB019 (Daclizumab High Yield Process) | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
BG9418 (Interferon beta-1a) | Phase 3 | Active Ulcerative Colitis | - | - |
Glatiramer Acetate | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
fampridine | Phase 3 | Multiple Sclerosis | - | - |
BG00012 (dimethyl fumarate) | Phase 3 | Healthy | - | - |
BG00002 (natalizumab) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Alefacept | Phase 3 | Chronic Plaque Psoriasis | - | - |
Omaveloxolone | Phase 3 | Friedreich Ataxia | - | - |
Bardoxolone Methyl | Phase 3 | Alport Syndrome | - | - |
Interferon Beta-1a | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - | - |
Interferon β-1a | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
tonapofylline | Phase 3 | Renal Insufficiency | - | - |
Diroximel fumarate | Phase 3 | Relapsing Forms of Multiple Sclerosis | - | - |
lixivaptan | Phase 3 | Hyponatremia | - | - |
Sertraline | Phase 3 | Depressive Disorder, Major | - | - |
Rituxan, Cyclophosphamide, Vincristine, Prednisone | Phase 3 | Immune Thrombocytopenic Purpura | - | - |
baricitinib treatment | Phase 3 | Rheumatoid Arthritis | - | - |
Mycophenolate Mofetil (cellcept) | Phase 3 | Multiple Sclerosis | - | - |
anti-TNF therapy | Phase 3 | Rheumatoid Arthritis | - | - |
Anti-inflammatory drugs | Phase 3 | Rheumatoid Arthritis | - | - |
ASA | Phase 3 | Healthy | - | - |
rituximab [MabThera/Rituxan] | Phase 3 | Rheumatoid Arthritis | - | - |
Desvenlafaxine | Phase 3 | Depressive Disorder, Major | - | - |
BIIB033 | Phase 2 | Multiple Sclerosis | - | - |
MOR202 | Phase 2 | Glomerulonephritis | - | - |
BIIB147 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
BCNU | Phase 2 | Lymphoma | - | - |
Transitioning patients from cyclosporine to alefacept | Phase 2 | Psoriasis | - | - |
Rituxan | Phase 2 | Lymphoma | - | - |
Bardoxolone methyl capsules | Phase 2 | IgA Nephropathy | - | - |
Mechanism of action of alefacept | Phase 2 | Psoriasis | - | - |
BIIB111 | Phase 2 | Choroideremia | - | - |
Levodopa | Phase 2 | Parkinson Disease | - | - |
Chemotherapy and Radioimmunotherapy | Phase 2 | Non-Hodgkin Lymphoma | - | - |
90-Y-ibritumomab tiuxetan | Phase 2 | Lymphoma | - | - |
Bardoxolone Methyl (RTA 402) | Phase 2 | Chronic Kidney Disease | - | - |
natalizumab IV | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
BG00002-E (natalizumab high titer) | Phase 2 | Multiple Sclerosis | - | - |
Ad.hIFN-β (BG00001, IDEC-201) | Phase 2 | Colorectal Carcinoma | - | - |
IDEC-114 | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
tetanus diphtheria toxoids vaccine | Phase 2 | Relapsing Forms of Multiple Sclerosis | - | - |
Baminercept alfa 1 | Phase 2 | Rheumatoid Arthritis | - | - |
BIIB074 | Phase 2 | Primary Inherited Erythromelalgia | - | - |
VP -16 | Phase 2 | Lymphoma | - | - |
Omaveloxolone Capsules (/capsule) | Phase 2 | Melanoma | - | - |
Omaveloxolone Lotion | Phase 2 | Breast Cancer | - | - |
Bardoxolone methyl (amorphous dispersion) | Phase 2 | Renal Insufficiency, Chronic | - | - |
Yttrium-ibritumomab (Zevalin) | Phase 2 | Lymphoma, Mantle-Cell | - | - |
BIIB080 | Phase 2 | Alzheimer Disease | OrphanFast TrackBreakthrough | - |
Omaveloxolone Ophthalmic | Phase 2 | Inflammation and Pain Following Ocular Surgery | - | - |
APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
RTA 402 (Bardoxolone Methyl) | Phase 2 | Diabetic Nephropathy | - | - |
Antiparkinsonian Agent(s) | Phase 2 | Parkinson Disease | - | - |
Diranersen | Phase 2 | Mild Cognitive Impairment Due to Alzheimer's Disease | - | - |
BIIB059 (litifilimab) | Phase 2 | Systemic Lupus Erythematosus | - | - |
Baminercept alfa 3 | Phase 2 | Rheumatoid Arthritis | - | - |
Baminercept alfa 4 | Phase 2 | Rheumatoid Arthritis | - | - |
Baminercept alfa 2 | Phase 2 | Rheumatoid Arthritis | - | - |
Baminercept alfa 5 | Phase 2 | Rheumatoid Arthritis | - | - |
CVP | Phase 2 | Non-Hodgkins Lymphoma | - | - |
In Zevalin | Phase 2 | Lymphoma | - | - |
BG00011 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
Ibritumomab Tiuxetan | Phase 2 | Non-Hodgkins Lymphoma | - | - |
interferon beta 1-a | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | Phase 2 | Relapsing Forms of Multiple Sclerosis | - | - |
BIIB033 (anti-LINGO-1 mAb) | Phase 2 | Acute Optic Neuritis | - | - |
DRF | Phase 2 | Relapsing Forms of Multiple Sclerosis | - | - |
exemestane (Aromasin) | Phase 2 | Breast Cancer | - | - |
trivalent seasonal influenza vaccine | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
BIIB122 | Phase 2 | Parkinson Disease | - | - |
Methylprednisolone | Phase 2 | Graft Versus Host Disease | - | - |
Zevalin Radioimmunotherapy | Phase 2 | Lymphoma | - | - |
BIIB091 | Phase 2 | Relapsing Forms of Multiple Sclerosis | - | - |
SAGE-324 | Phase 2 | Essential Tremor | - | - |
CHOP | Phase 2 | Non-Hodgkins Lymphoma | - | - |
natalizumab SC | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
Y Zevalin | Phase 2 | Lymphoma | - | - |
Bardoxolone methyl oral capsule | Phase 2 | Chronic Kidney Diseases | - | - |
CNV1014802 | Phase 2 | Lumbosacral Radiculopathy | - | - |
BIIB104 | Phase 2 | Cognitive Impairment Associated With Schizophrenia | - | - |
Lumiliximab with FCR | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
BG9924 | Phase 2 | Rheumatoid Arthritis | - | - |
BIIB021 | Phase 2 | GIST | - | - |
Omaveloxolone Opthalmic | Phase 2 | Inflammation and Pain Following Ocular Surgery | - | - |
BIIB041 (PR Fampridine) | Phase 2 | Multiple Sclerosis | - | - |
Zevalin | Phase 2 | Lymphoma | - | - |
90Y Zevalin | Phase 2 | Non-Hodgkins Lymphoma | - | - |
Lecanemab | Phase 2 | Alzheimer's Disease | - | - |
BG00010 | Phase 2 | Painful Lumbar Radiculopathy | - | - |
Ibritumomab Tiuxetan (Zevalin) | Phase 2 | Lymphoma | - | - |
BIIB014 | Phase 2 | Parkinson's Disease | - | - |
Tyruko Injectable Product | Phase 2 | Multiple Sclerosis | - | - |
BIIB112 | Phase 2 | X-Linked Retinitis Pigmentosa | - | - |
Alzheimer Disease
2 drugs in this indication
Alzheimer's disease
2 drugs in this indication
C3G or Primary IC-MPGN in adolescents
2 drugs in this indication
ALS (SOD1)
1 drug in this indication
multiple myeloma
1 drug in this indication
Systemic Lupus Erythematosus
1 drug in this indication
Dravet Syndrome
1 drug in this indication
lupus
1 drug in this indication
cutaneous lupus erythematosus
1 drug in this indication
FSGS
1 drug in this indication
Geographic Atrophy Secondary to Age-related Macular Degeneration
1 drug in this indication
Early Alzheimer's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Biogen Inc.'s drug pipeline?→
CatalystAlert tracks 121 drug candidates in Biogen Inc.'s (BIIB) pipeline across Phase 3, Phase 2, Approved. Its lead program is Tofersen (Approved). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biogen Inc.'s next FDA catalyst?→
Biogen Inc.'s (BIIB) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIIB biotech catalysts?→
Add BIIB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biogen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
